ArticleRheumatology and therapy2026

Guselkumab Improves Patient-Reported Outcomes Among Participants with Psoriatic Arthritis and Inadequate Response to Tumor Necrosis Factor Inhibitors in the COSMOS Study.

Laure Gossec et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.